Search
Search Results
##search.searchResults.foundPlural##
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2585PDF: 836HTML: 1748 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2329PDF: 1862HTML: 896 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2339PDF: 870HTML: 1703Figure 1: 241Table 1: 250 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3391PDF: 988HTML: 3530 -
-
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1384PDF: 1106HTML: 439 -
-
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3016PDF: 1065HTML: 5653 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2778PDF: 810HTML: 2331 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1598HTML: 680PDF: 897 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1526PDF: 983HTML: 258 -
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
106PDF: 82Suppl. Files: 17Html: 16Html Suppl. Files: 15 -
-
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3431PDF: 1009HTML: 3004 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1687PDF: 1119HTML: 490 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3746PDF: 2616HTML: 1649 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
772PDF: 488HTML: 6286 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1396PDF: 629HTML: 4164 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2707PDF: 992HTML: 597 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1975PDF: 1064HTML: 251 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2143PDF: 880HTML: 262 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1377PDF: 958HTML: 343 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4519PDF: 1810HTML: 1126 -
TUBERCULOSIS IN TROPICAL AREAS AND IMMIGRANTS
3530PDF: 1390HTML: 6347 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2132PDF: 155HTML: 41 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3384PDF: 1771HTML: 1170
1 - 45 of 45 items







